



**1st quarter 2006  
Strong sales growth of 17%**

€ millions	2006 Q1	2005 Q1	% growth
France	20,66	17,70	+17%
Subsidiaries (1)	11,47	9,66	+19% (2)
Distributors	3,46	2,94	+18%
<b>Total</b>	<b>35,59</b>	<b>30,30</b>	<b>+17%</b>

(1) Germany, Italy, Spain/Portugal, Belgium

(2) + 9% organic growth

- Sales in the first quarter again grew significantly in all markets.
- Growth in France of 17% and in the subsidiaries (9% organic) is based on strong growth in initial treatments.
- Stallergènes continues to increase its market share due to an enlarged innovative commercial service offering and continuous growth in desensitisation by the sublingual route. This also benefited from the positive impact of the clinical study ORALAIR® Grasses communicated at the end of 2005.
- Sales to distributors again started to grow (up 18%).
- This good start to the year supports the target of growth close to 10% for 2006.

## **About STALLERGENES**

*Stallergènes Group is today the world's leading pharmaceutical laboratory specialising in allergen immunotherapy, both in terms of number of patients treated (N°1) and sales (N°2). In its 40 years of existence, Stallergènes has established itself as a dynamic player, frequently as an innovator, in the battle to prevent and cure allergies, rhinitis and asthma in particular. Stallergènes devotes over 15% of its sales to its Research and Development activities. Stallergènes' development is focused on the French market and on international markets through its subsidiaries based in Germany, Spain, Italy, Portugal and Belgium, and its distributors based in Eastern Europe, North Africa and elsewhere.*

*Shares of the Group's parent company, Stallergènes SA, are listed on the Eurolist Compartment B of the Euronext Paris Stock Exchange.*

*ISIN Code: FR0000065674*

*Reuters Code: GEN.PA*

*Bloomberg Code: GEN.FP*



### **STALLERGENES**

Albert SAPORTA – Chairman and CEO

Christian THIRY – Chief Financial Officer

Tél : +33 (0)1 55 59 20 95

[investorrelations@stallergenes.fr](mailto:investorrelations@stallergenes.fr)

### **PAVIE FINANCE**

Lucile de FRAGUIER  
Investor & Analyst Relations  
Tel: + 33 (0)1 42 15 04 39  
[contact@pavie-finance.com](mailto:contact@pavie-finance.com)